Sofinnova Investments’s Vertex Pharmaceuticals VRTX Stock Holding History

Sofinnova Investments’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-164,594	Closed	-$74.6M	–	88
2025 Q4	$74.6M	Buy	164,594 +46,719	+40%	+$20.1M	3.22%	7
2025 Q3	$46.2M	Buy	+117,875	New	+$49.3M	2.52%	14
2023 Q3	–	Sell	-145,300	Closed	-$51.1M	–	77
2023 Q2	$51.1M	Buy	+145,300	New	+$49M	3.35%	9
2023 Q1	–	Sell	-156,989	Closed	-$45.3M	–	63
2022 Q4	$45.3M	Buy	+156,989	New	+$47.8M	2.69%	10
2022 Q3	–	Sell	-74,758	Closed	-$21.1M	–	64
2022 Q2	$21.1M	Sell	74,758 -20,245	-21%	-$5.42M	1.75%	15
2022 Q1	$24.8M	Buy	+95,003	New	+$22.5M	1.88%	12
2021 Q3	–	Sell	-88,214	Closed	-$17.8M	–	85
2021 Q2	$17.8M	Buy	88,214 +42,514	+93%	+$8.89M	1.03%	28
2021 Q1	$9.82M	Buy	+45,700	New	+$10M	0.59%	33
2020 Q2	–	Sell	-85,664	Closed	-$20.4M	–	90
2020 Q1	$20.4M	Sell	85,664 -53,500	-38%	-$12.3M	1.89%	14
2019 Q4	$30.5M	Buy	139,164 +17,474	+14%	+$3.54M	2.2%	11
2019 Q3	$20.6M	Buy	121,690 +71,389	+142%	+$12.6M	1.86%	16
2019 Q2	$9.22M	Buy	+50,301	New	+$8.79M	0.85%	29

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sofinnova Investments's VRTX Position: Q1 2026 in Review

Sofinnova Investments sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 164,594 shares — an estimated $74.6M sold.

Sofinnova Investments first reported a position in VRTX in Q2 2019 and held it in 12 quarters. The position peaked at $74.6M in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Sofinnova Investments reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Sofinnova Investments sold 164,594 Vertex Pharmaceuticals shares in Q1 2026, an estimated $74.6M.
Sofinnova Investments first reported a position in Vertex Pharmaceuticals in Q2 2019 and held it in 12 quarters.
Sofinnova Investments's Vertex Pharmaceuticals position peaked at $74.6M in Q4 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Sofinnova Investments's 13F filing for Q1 2026, filed 15 May 2026.